| Product Code: ETC7657143 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Non-Cardioselective Beta Blockers Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Non-Cardioselective Beta Blockers Market - Industry Life Cycle |
3.4 Israel Non-Cardioselective Beta Blockers Market - Porter's Five Forces |
3.5 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.6 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume Share, By Target, 2021 & 2031F |
3.7 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.8 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.9 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.10 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Israel Non-Cardioselective Beta Blockers Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of hypertension and other cardiovascular diseases in Israel |
4.2.2 Growing awareness about the benefits of non-cardioselective beta blockers in managing cardiovascular conditions |
4.2.3 Technological advancements in drug delivery systems and formulations improving the efficacy of non-cardioselective beta blockers |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval and market entry in Israel |
4.3.2 Potential side effects and safety concerns associated with non-cardioselective beta blockers |
4.3.3 Competition from alternative treatment options such as cardioselective beta blockers or other classes of cardiovascular drugs |
5 Israel Non-Cardioselective Beta Blockers Market Trends |
6 Israel Non-Cardioselective Beta Blockers Market, By Types |
6.1 Israel Non-Cardioselective Beta Blockers Market, By Indication |
6.1.1 Overview and Analysis |
6.1.2 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Indication, 2021- 2031F |
6.1.3 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Angina, 2021- 2031F |
6.1.4 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Hypertension, 2021- 2031F |
6.1.5 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Heart Failure, 2021- 2031F |
6.1.6 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Arrhythmias, 2021- 2031F |
6.1.7 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Israel Non-Cardioselective Beta Blockers Market, By Target |
6.2.1 Overview and Analysis |
6.2.2 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Beta-1 Receptors, 2021- 2031F |
6.2.3 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Beta-2 Receptors, 2021- 2031F |
6.2.4 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Israel Non-Cardioselective Beta Blockers Market, By Drugs |
6.3.1 Overview and Analysis |
6.3.2 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Propranolol, 2021- 2031F |
6.3.3 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Nadolol, 2021- 2031F |
6.3.4 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Labetalol, 2021- 2031F |
6.3.5 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Carvedilol, 2021- 2031F |
6.3.6 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Sotalol, 2021- 2031F |
6.3.7 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Timolol, 2021- 2031F |
6.3.8 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Others, 2021- 2031F |
6.3.9 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Israel Non-Cardioselective Beta Blockers Market, By Route of Administration |
6.4.1 Overview and Analysis |
6.4.2 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Oral, 2021- 2031F |
6.4.3 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.4.4 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Israel Non-Cardioselective Beta Blockers Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.5.3 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Homecare, 2021- 2031F |
6.5.4 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.5.5 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Others, 2021- 2031F |
6.6 Israel Non-Cardioselective Beta Blockers Market, By Distribution Channel |
6.6.1 Overview and Analysis |
6.6.2 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.6.3 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.6.4 Israel Non-Cardioselective Beta Blockers Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
7 Israel Non-Cardioselective Beta Blockers Market Import-Export Trade Statistics |
7.1 Israel Non-Cardioselective Beta Blockers Market Export to Major Countries |
7.2 Israel Non-Cardioselective Beta Blockers Market Imports from Major Countries |
8 Israel Non-Cardioselective Beta Blockers Market Key Performance Indicators |
8.1 Number of prescriptions filled for non-cardioselective beta blockers in Israel |
8.2 Patient adherence rates to non-cardioselective beta blocker treatment regimens |
8.3 Rate of new product development and innovations in the non-cardioselective beta blocker market in Israel |
9 Israel Non-Cardioselective Beta Blockers Market - Opportunity Assessment |
9.1 Israel Non-Cardioselective Beta Blockers Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.2 Israel Non-Cardioselective Beta Blockers Market Opportunity Assessment, By Target, 2021 & 2031F |
9.3 Israel Non-Cardioselective Beta Blockers Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.4 Israel Non-Cardioselective Beta Blockers Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.5 Israel Non-Cardioselective Beta Blockers Market Opportunity Assessment, By End User, 2021 & 2031F |
9.6 Israel Non-Cardioselective Beta Blockers Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Israel Non-Cardioselective Beta Blockers Market - Competitive Landscape |
10.1 Israel Non-Cardioselective Beta Blockers Market Revenue Share, By Companies, 2024 |
10.2 Israel Non-Cardioselective Beta Blockers Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here